WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007011875) TREATMENT OF CONDITIONS ASSOCIATED WITH THE PRESENCE OF MACROMOLECULAR AGGREGATES, PARTICULARLY OPHTHALMIC DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/011875    International Application No.:    PCT/US2006/027686
Publication Date: 25.01.2007 International Filing Date: 14.07.2006
IPC:
A61K 9/00 (2006.01)
Applicants: CHAKSHU RESEARCH INC. [US/US]; 130 Knowles Drive, Suite A, Los Gatos, CA 95032 (US) (For All Designated States Except US).
BHUSHAN, Rajiv [IN/US]; (US) (For US Only).
GIN, Jerry, B. [US/US]; (US) (For US Only)
Inventors: BHUSHAN, Rajiv; (US).
GIN, Jerry, B.; (US)
Agent: REED, Dianne, E.; MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C., 1400 Page Mill Road, Palo Alto, California 94304 (US)
Priority Data:
11/182,999 15.07.2005 US
Title (EN) TREATMENT OF CONDITIONS ASSOCIATED WITH THE PRESENCE OF MACROMOLECULAR AGGREGATES, PARTICULARLY OPHTHALMIC DISORDERS
(FR) TRAITEMENT D'AFFECTIONS ASSOCIES A LA PRESENCE D'AGREGATS MACROMOLECULAIRES, NOTAMMENT DE TROUBLES OPHTALMIQUES
Abstract: front page image
(EN)A method and formulation are provided for the treatment of medical conditions associated with the formation and/or deposition of macromolecular aggregates, particularly those associated with adverse ocular conditions. The formulation contains a non-cytotoxic chelating agent containing at least three negatively charged chelating atoms and a charge-masking agent containing at least one polar group and having a molecular weight of less than about 250, wherein the molar ratio of the charge-masking agent to the chelating agent is sufficient to ensure that substantially all negatively charged chelating atoms are associated with a polar group on the charge-masking agent.
(FR)L'invention concerne un procédé et une formulation pour le traitement d'affections médicales associées à la formation et/ou au dépôt d'agrégats macromoléculaires, notamment ceux associés aux affections oculaires critiques. Cette formulation contient un agent chélateur non cytotoxique contenant au moins trois atomes de chélation chargés négativement et un agent de masquage de charge contenant au moins un groupe polaire et possédant un poids moléculaire de moins d'environ 250, le rapport molaire entre l'agent de masquage de charge et l'agent chélateur étant suffisant pour assurer que sensiblement tous les atomes de chélation chargés négativement soient associés à un groupe polaire sur l'agent de masquage de charge.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)